Mouse Monoclonal CHRNB3 Antibody

The CHRNB3 antibody targets the β3 subunit of neuronal nicotinic acetylcholine receptors (nAChRs), which are ligand-gated ion channels critical for synaptic transmission in the nervous system. The CHRNB3 gene encodes a protein that combines with other subunits (e.g., α6) to form functional receptors, predominantly expressed in dopaminergic pathways of the brain, including the substantia nigra and ventral tegmental area. These receptors modulate neurotransmitter release, influencing reward, addiction, and motor control. Research on CHRNB3 antibodies has grown due to their role in studying receptor localization, expression patterns, and dysfunction in neurological disorders. For instance, variants in CHRNB3 are linked to nicotine dependence, Parkinson’s disease, and epilepsy. Antibodies against CHRNB3 enable immunohistochemical detection, Western blotting, and mechanistic studies in animal models, aiding in understanding receptor assembly, trafficking, and signaling. Additionally, CHRNB3 antibodies are explored as potential therapeutic tools or diagnostic markers for conditions involving cholinergic system dysregulation. However, challenges remain in ensuring antibody specificity due to structural homology among nAChR subunits. Ongoing studies aim to refine antibody validation techniques and expand applications in neuropharmacology and disease modeling.